Buprenorphine/Naloxone Therapy (BT): Definition, Application, Process, Side Effects, and Regulation

Buprenorphine/Naloxone therapy (BT) is a dual-action therapy specifically designed to treat opioid dependence by cutting down cravings, alleviating withdrawal symptoms, and preventing misuse. BT is widely used for managing opioid dependence and is FDA-approved for substance use disorders. This approach decreases the risk of misuse, especially with the addition of naloxone, which blocks opioid effects. A study found that 69.2% of extended-release buprenorphine (XRB) patients stayed in treatment vs. 34.6% for sublingual buprenorphine-naloxone (SLB), with fewer clinic visits (0.11/day vs. 1.06/day) and higher opioid-negative tests (55.3% vs. 38.4%).

No serious adverse events or overdoses occurred, suggesting XRB improved treatment retention and simplified care in correctional settings, according to Lee et al. 2021 in “Retention of Adults With Opioid Addiction Using Extended-Release Buprenorphine vs Daily Buprenorphine-Naloxone Post-Jail.”

Buprenorphine/Naloxone therapy is applied in opioid dependence treatment through Medication-Assisted Treatment (MAT), covering maintenance therapy and withdrawal symptom management. BT helps minimize the risk of relapse and is combined with therapies like cognitive behavioral therapy (CBT) to bolster outcomes. Buprenorphine is a long-acting opioid with a high affinity for the mu-opioid receptor. A daily dose of 4 mg binds about 50% of these receptors, effectively suppressing withdrawal symptoms.

A 16 mg dose binds around 80% of the receptors, enough to block the euphoric effects of most abused opioids, as observed by Greenwald et al. 2014 in “Buprenorphine Maintenance and mu-Opioid Receptor Availability in the Treatment of Opioid Use Disorder: Implications for Clinical Use and Policy.”

The treatment process involves an initial assessment, followed by a medical evaluation to determine eligibility. During the induction phase, patients receive their first doses, transitioning to the stabilization phase to manage cravings. In the maintenance phase, the dosage is adjusted, and eventually, tapering or discontinuation occurs if clinically indicated. A study revealed that an additional 100 days of buprenorphine treatment lessened the risk of opioid overdose by 36% among patients with opioid use disorder who received at least one buprenorphine dispensing, as analyzed by Sun et al. 2021 in “Evaluation of the Effectiveness of Buprenorphine-Naloxone on Opioid Overdose and Death among Insured Patients with Opioid Use Disorder in the United States.”

Common side effects of buprenorphine-naloxone encompass respiratory depression, nausea, and headaches. Some patients experience constipation or dizziness. These effects are manageable and vary based on dosage and individual health conditions. Additionally, the pharmacokinetics of the two drugs contribute to their side effect profiles. For instance, buprenorphine has a considerably higher sublingual bioavailability (40%) than naloxone (10%), making buprenorphine the predominant effect. Moreover, buprenorphine has a 10 times longer duration of action (966 min) compared to naloxone’s (105 min) in intravenous form, which also influences the likelihood and persistence of certain side effects, as highlighted by Chen et al. 2014 in “Buprenorphine–Naloxone Therapy in Pain Management.”

Buprenorphine/Naloxone therapy is subject to Federal regulations like the Drug Addiction Treatment Act (DATA) 2000 and CARA govern the prescription of Suboxone. These rules require special certification for healthcare providers to ensure safe administration and safeguarding against misuse while ensuring effective pain management for patients.

What Is Buprenorphine/Naloxone Therapy (BT)?

Buprenorphine/Naloxone therapy (BT) is a treatment for opioid use disorder, combining buprenorphine-naloxone to reduce cravings and prevent withdrawal without causing euphoria. The buprenorphine component binds to the mu-opioid receptor, easing withdrawal and cravings, while naloxone blocks the euphoric effects of opioids if misused. This combination not only mitigates the risk of overdose but also lowers the potential for abuse

This therapy has been FDA-approved for the treatment of opioid use disorder and has demonstrated substantial efficacy in cutting the risk of relapse and overdose. Suboxone, a popular form of buprenorphine-naloxone, is prescribed as part of opioid dependence treatment and maintenance therapy.

Buprenorphine is classified as a Schedule III drug, indicating it has a moderate-to-low potential for physical dependence and a higher potential for psychological dependence. Approved by the U.S. Food and Drug Administration (FDA), buprenorphine is used to treat both acute and chronic pain as well as opioid dependence. Naloxone, on the other hand, is exempt from DEA scheduling and is classified as a legend drug.

In 2023, over 2.1 million naloxone prescriptions were dispensed from retail pharmacies. The rate of naloxone dispensed in the U.S. increased from 0.3 to 0.6 per 100 persons between 2019 and 2023, as reported by the Centers for Disease Control (2024).

How Is Buprenorphine/Naloxone Therapy (BT) Used for Addiction Treatment?

Buprenorphine/naloxone therapy (BT) is used for addiction treatment by combining a treatment designed to treat opioid dependence through medication-assisted treatment (MAT). BT stabilizes individuals in recovery, manages withdrawal symptoms, and supports relapse prevention. Among patients treated with buprenorphine, each additional month of treatment was associated with a 17% to 25% decrease in the odds of nonprescribed opioid use in the past 30 days.

Clinicians are able to use these findings in shared decision-making to emphasize the importance of sustained retention in MOUD (medications for opioid use disorder), as detailed by Jiang et al. 2024 in “Association Between Length of Buprenorphine or Methadone Use and Nonprescribed Opioid Use Among Individuals with Opioid Use Disorder: A Cohort Study.”

Buprenorphine/Naloxone Therapy (BT) is used for addiction treatment in the following ways:

• Opioid Dependence Treatment
• Maintenance Therapy
• Detoxification
• Induction Therapy
• Medication-Assisted Treatment (MAT)
• Withdrawal Symptom Management
• Relapse Prevention

The 7 common ways buprenorphine/naloxone therapy (BT) is used for addiction treatment are given below:

Opioid Dependence Treatment

Opioid dependence treatment with buprenorphine/naloxone helps individuals reduce cravings and opioid use. BT is used as part of a broader approach to manage opioid dependence, involving maintenance therapy to keep patients in a stable state, while the combination of buprenorphine and naloxone blocks opioid receptors and minimizes the euphoria that evokes relapse. Opioids are responsible for more than 120,000 deaths worldwide each year, as attributed by Dydyk et al. 2024 in “Opioid Use Disorder.” This highlights the global impact of opioid addiction and underscores the urgent need for effective treatment strategies to reduce these fatalities.

Maintenance Therapy

Maintenance therapy with buprenorphine/naloxone ensures long-term management of opioid dependence. BT allows patients to plateau their condition without the need for constant cravings or opioid use. BT cuts illicit opioid use and grants sustainability during the recovery process.

Detoxification

Detoxification with buprenorphine/naloxone entails gradually tapering opioid use under medical supervision. During detoxification, Buprenorphine’s long-acting properties support the lowering of withdrawal symptoms, while naloxone precludes misuse, allowing individuals to detox safely.

Induction Therapy

Induction therapy with buprenorphine/naloxone transitions individuals from opioid use to treatment. Induction therapy starts when the patient is in early withdrawal, and buprenorphine/naloxone is introduced to assuage symptoms and intercept further opioid use.

Medication-Assisted Treatment (MAT)

Medication-assisted treatment (MAT) amalgamates buprenorphine and naloxone to treat opioid use disorder. MAT tackles the physiological and psychological components of addiction, enhancing the effectiveness of other treatment modalities, including therapy and counseling.

Withdrawal Symptom Management

Buprenorphine/naloxone is tremendously effective in withdrawal symptom management, blocking grave withdrawal symptoms that provoke patients to relapse. The medication slowly offers victims equilibrium in the patient’s brain chemistry and lessens discomfort associated with opioid withdrawal.

Relapse Prevention

Buprenorphine/naloxone therapy staves off relapse prevention, impeding the euphoric effects of opioids. The therapy provides a safer environment for recovery and brings down the risk of returning to opioid use by chopping down pining and preserving the patient’s condition. The relapse rate for opioid addiction is higher compared to other substance dependencies, with research showing that up to 91% of individuals with opioid addiction experience relapse. This suggests that the risk of relapse in opioid addiction exceeds that seen in other drug addictions, as cited by Kadam et al. 2017 in “A Comparative Study of Factors Associated with Relapse in Alcohol Dependence and Opioid Dependence.”

What Is the Process of Buprenorphine/Naloxone Therapy (BT) for Addiction Treatment?

The process of Buprenorphine/Naloxone Therapy (BT) for addiction treatment involves seven main steps:

• Initial Assessment
• Medical Evaluation
• Eligibility Determination
• Induction Phase
• Stabilization Phase
• Maintenance Phase
• Tapering or Discontinuation

The steps listed are important stages in administering BT for addiction, ensuring patient safety, monitoring, and long-term success in treating opioid dependence through managed care. However, not all patients engage in the necessary follow-up care. For instance, refusal of further medical assistance after an initial treatment, such as naloxone administration, is a huge barrier. A Kentucky study found that 20% of individuals treated by EMS for opioid overdoses refused transport to an ED from January 14 to April 26, 2020. NEMSIS data showed transport refusal rose from 15% in 2018 to 22% in 2022. Reasons included withdrawal symptoms, concerns about hospital care, and fear of stigmatization, as noted by Casillas et al. 2024 in “Comparison of Emergency Medical Services and Emergency Department Encounter Trends for Nonfatal Opioid-Involved Overdoses, Nine States, United States, 2020–2022.”

The following are 7 steps in the process used in BT for addiction treatment:

Step 1: Initial Assessment

The initial assessment gathers a comprehensive understanding of the patient’s opioid use history, previous treatments, and current withdrawal symptoms. Healthcare providers conduct a thorough review to understand the severity of the opioid use disorder (OUD) and any co-occurring conditions like mental health disorders. This step is integral in determining the next course of action.

• Prevalence of OUD:  About 2.7 million people in the U.S. suffer from opioid use disorder (OUD), but only 1.1 million receive the necessary treatment, according to the National Institute on Drug Abuse (2020) in “Medications to Treat Opioid Use Disorder Research Report.”
• Insurance and Eligibility: Insurance coverage for addiction treatment varies. Most Medicaid programs cover opioid agonist therapy, including buprenorphine/naloxone, but private insurance plans differ in their coverage, especially regarding treatment duration and eligibility criteria.

Step 2: Medical Evaluation

Following the assessment, a medical evaluation determines if the patient is fit to start Buprenorphine/Naloxone therapy. This step includes physical exams, blood tests, and urine screenings to rule out any health issues that complicate treatment. Mental health assessments are conducted to ensure that co-occurring psychiatric conditions are appropriately managed during therapy.

• Data Insight: A study found that 64.3% of adults with OUD reported having any mental illness (AMI), while approximately 26.9% had a serious mental illness (SMI), as elaborated by Jones M. &McCance-Katz E. 2018  in “Co-occurring Substance Use and Mental Disorders Among Adults with Opioid Use Disorder.” These conditions require careful evaluation and management, as untreated mental health issues hinder recovery efforts.

Step 3: Eligibility Determination

In this phase, providers confirm whether the patient meets the diagnostic criteria for opioid use disorder (OUD), typically using tools like the Diagnostic and Statistical Manual of Mental Disorders (DSM-5). Eligibility is based on the extent of opioid dependence, history of opioid misuse, and whether the patient has had previous attempts at opioid treatment.

• OUD Statistics: Opioid use among 190 patients decreased massively from 22.3% to 11.0% after six months of treatment as analyzed in the study “Outcomes from the Medication-Assisted Treatment Pilot Program for Adults with Opioid Use Disorders in Rural Colorado” by Amura et al. 2022. This shows individuals diagnosed with OUD will benefit from medication-assisted treatment (MAT) like Buprenorphine/Naloxone, but barriers such as stigma, insurance limitations, and lack of access to care prevent many from receiving treatment.
• Insurance Coverage: For eligible individuals, the use of MAT is widely covered by Medicaid and some private insurance, though access is still a challenge due to regional and economic factors.

Step 4: Induction Phase

The induction phase marks the beginning of Buprenorphine/Naloxone treatment. During this phase, patients receive their first doses of the medication under close medical supervision. The goal is to alleviate withdrawal symptoms and reduce cravings while gradually introducing the patient to a stable dose. Monitoring during this phase ensures the patient adjusts to the medication without experiencing respiratory depression or other side effects.

• Withdrawal Data: People who struggle with opioid addiction experience withdrawal symptoms at some point during recovery, making a supervised induction phase vital to minimize discomfort and risks. Opioid withdrawal symptoms were reported by 85% of participants in the last six months, with 29% experiencing withdrawal at least once a month and 35% at least once a week. Additionally, 57% of 814 people who inject drugs (PWID), who used opioids regularly (at least 12 times in the past 30 days), described their withdrawal symptoms as very or extremely painful as detailed by Bluthenthal et al. 2020 in “Opioid Withdrawal Symptoms, Frequency, and Pain Characteristics as Correlates of Health Risk Among People Who Inject Drugs.”
• Normal Duration: The induction phase lasts a few days, with close monitoring to adjust the dose appropriately for effective symptom control.

Step 5: Stabilization Phase

Once the induction phase is complete, patients enter the stabilization phase. During this phase, the dosage of Buprenorphine/Naloxone is adjusted to find the optimal level that controls withdrawal symptoms and cravings without causing adverse effects. This phase lasts several weeks, and the primary goal is to ensure the patient is on the appropriate dosage for ongoing recovery.

• Data on Stabilization: Buprenorphine treatment was associated with a 76% decreased risk of overdose within 3 months and a 59% decline within 12 months. Similarly, it diminished serious opioid-related acute care use by 32% at 3 months and by 26% at 12 months. These findings highlight the importance of addressing the underuse of buprenorphine and methadone for treating OUD, as noted by Wakeman et al. 2020 in “Comparative Effectiveness of Different Treatment Pathways for Opioid Use Disorder.”
• Adverse Effects: The stabilization phase must monitor for potential adverse effects like respiratory depression, especially during dose adjustments. A recent study indicates that respiratory depression occurs more frequently during initial dosing or rapid dose escalations.

Step 6: Maintenance Phase

During the maintenance phase, patients remain on a stable, long-term dose of Buprenorphine/Naloxone. The goal is to maintain recovery by preventing relapse and managing cravings. Patients are also encouraged to participate in medication-assisted treatment (MAT) programs, which are therapy and support groups. The maintenance phase supports long-term recovery and the prevention of relapse into opioid misuse.

• Efficacy Data: A trial of 653 patients with prescription opioid dependence found that only 6.6% succeeded after a 4-week buprenorphine-naloxone treatment, increasing to 49.2% during a 12-week extended treatment. Success dropped to 8.6% eight weeks post-taper. Counseling had no impact on outcomes. Heroin history reduced success rates, but chronic pain did not. Sustained treatment of buprenorphine-naloxone cuts opioid use, as put forward by Weiss et al. 2011 in “Adjunctive Counseling During Brief and Extended Buprenorphine-Naloxone Treatment for Prescription Opioid Dependence.”
• Long-Term Recovery: Maintenance on Buprenorphine/Naloxone drops the risk of opioid overdose, with receiving buprenorphine after a nonfatal opioid overdose is associated with a 62% drop in the risk of subsequent opioid overdose death as published by Rutgers University in “Buprenorphine After Nonfatal Opioid Overdose Results in Reduced Risk of Overdose Death.”

Step 7: Tapering or Discontinuation

The tapering or discontinuation phase occurs when a patient is ready to reduce or stop medication. The process involves a gradual reduction in the dose to minimize withdrawal symptoms and to ensure the patient manages without the medication. This step is carefully managed to prevent relapse and ensure the patient remains stable during the transition.

• Tapering Statistics: A study comparing 7-day and 28-day buprenorphine tapering schedules among 516 participants found that 44% of the 7-day group provided opioid-free urine samples at taper completion, compared to 30% of the 28-day group. Outcomes at 1-month and 3-month follow-ups showed no differences between groups, with opioid-free rates of 18% and 12% for the 7-day taper and 18% and 13% for the 28-day taper, respectively. The findings suggest no benefit in prolonging taper duration for discontinuing buprenorphine treatment, as demonstrated by Ling et al. 2009 in “Buprenorphine Tapering Schedule and Illicit Opioid Use.”

Successful tapering depends on the patient’s overall recovery, including support systems and treatment engagement.

• Withdrawal Risks: Abrupt discontinuation or too rapid tapering upsurges the likelihood of relapse.

How Long Is Buprenorphine/ Naloxone Therapy (BT) Treatment?

Buprenorphine/ Naloxone Therapy takes a minimum treatment duration of 8 weeks to achieve the necessary results, particularly in steadying patients and halting relapse. Participation in treatment for less than 90 days is considered to have limited effectiveness as put forth by Kumar et al. 2024 in “Buprenorphine.” The American Society of Addiction Medicine (ASAM) states that there is no recommended duration for buprenorphine treatment.

What Are the Side Effects of Buprenorphine/Naloxone Therapy (BT)?

The common side effects of Buprenorphine/Naloxone Therapy (BT) include respiratory depression, nausea, headaches, dizziness, constipation, sweating, and sleep disturbances. Buprenorphine-naloxone treatment has major side effects on patients dealing with opioid use disorder and substance use disorders, especially when dosages are not properly adjusted. Although buprenorphine/naloxone (bup/nal) has a generally favorable pharmacological profile, it produces adverse effects, primarily due to drug-drug interactions. In a study by Alho et al. 2006 titled “Abuse Liability of Buprenorphine-Naloxone Tablets in Untreated IV Drug Users,” around 80% of opioid-dependent individuals who switched from buprenorphine to bup/nal reported a negative experience, and fewer than 20% felt the two drugs were comparable. The common side effects of bup/nal therapy are given below :

Physical Side Effects of Buprenorphine/Naloxone Therapy (BT)

The physical side effects of BT are respiratory depression, nausea, headaches, dizziness, constipation, and physical fatigue. These effects happen due to the medication’s action on the mu-opioid receptors and other systems in the body. While manageable, these side effects require attention during treatment. Resting on data from Drugs.com in their “Buprenorphine / Naloxone Side Effects” section, the side effects are categorized by their frequency of occurrence, ranging from very common to rare, with definitions provided for each category:

The common physical side effects of BT are given below:

• Respiratory depression: Respiratory depression occurs when buprenorphine suppresses the body’s natural drive to breathe. Respiratory depression swings from mild to severe, particularly with higher doses. Respiratory depression is dangerous if not monitored closely. Common signs are shallow or slow breathing, difficulty breathing, and increased sleepiness. Respiratory depression has a 1%-10% incidence occurrence.
• Nausea: Nausea arises from buprenorphine’s effects on the central nervous system and gastrointestinal system. The nausea is mild to moderate and tends to subside after the body adjusts to the medication. Common symptoms are feeling queasy and vomiting. This side effect is short-term and occurs most during the early stages of treatment or after dose changes.
• Headaches: Headaches are caused by buprenorphine’s interaction with the brain’s chemistry, particularly its effect on neurotransmitters that regulate pain and blood vessel dilation. Common types of headaches are tension-type headaches and throbbing pain. Headaches tend to be short-term but persist during dose increases or early treatment. Headaches are 1%–10% are frequent.
• Dizziness: Buprenorphine evokes dizziness by lowering blood pressure and affecting the balance mechanisms in the inner ear, especially during the induction phase or when doses are increased. Symptoms of dizziness are lightheadedness, vertigo, and feeling faint. This effect is short-term but lasts as long as the body is adjusting to the medication.
• Constipation: As an opioid, buprenorphine slows down intestinal movement by binding to opioid receptors in the gut, leading to constipation. This is a common side effect of opioid treatments. Symptoms are difficulty passing stools, bloating, and discomfort. Constipation is long-term if not managed but alleviated with lifestyle changes or additional medication.

Most of these side effects resolve within 1-2 weeks of treatment.

Psychological Side Effects of Buprenorphine/Naloxone Therapy (BT)

The psychological side effects of Buprenorphine/Naloxone therapy (BT) are depression, anxiety, irritability, and mood swings, attributed to the medication’s interaction with the brain’s opioid receptors and its effect on neurotransmitter regulation. These psychological side effects are short-term, but in some cases, they persist, certainly if the dosage is not well-tolerated.

These side effects include:

• Anxiety: Buprenorphine causes changes in serotonin and dopamine levels, which adds to anxiety in some individuals. Anxiety is a common side effect (1%–10%), impacting a portion of those undergoing treatment.
• Mood swings: As an opioid agonist, buprenorphine induces mood fluctuations due to its effect on brain chemistry, resulting in periods of irritability or emotional instability. These are common (1%–10%), particularly during the initiation phase or dose changes.
• Depression: The opioid effects of buprenorphine alter brain neurotransmitters, leading to depressive symptoms in some patients. Depression is also common (1%–10%) and occurs in conjunction with other psychological effects.
• Irritability: Buprenorphine’s interaction with opioid receptors brings about irritability, especially during the initiation phase or dosage adjustments. This side effect falls within the common (1%–10%) range, indicating its prevalence among those adjusting to treatment.

What Are the Side Effects of Buprenorphine/Naloxone Therapy (BT) in the Elderly?

The side effects of Buprenorphine/Naloxone (Bup/Nal) therapy in the elderly are more severe respiratory depression, dizziness, constipation, and gastrointestinal issues such as nausea and abdominal pain. Moreover, mental health effects like anxiety, mood swings, and depression are more pronounced. Cardiovascular effects, including hypotension, palpitations, and bradycardia, are also of concern. These side effects are orders of magnitude severe in the elderly due to their diminished liver and kidney function, making careful monitoring and dose adjustments necessary.

Six opioid-naïve elderly hospitalized patients experienced respiratory and neurological depression after receiving buprenorphine for acute pain management over 24 months, as investigated in a study titled “Buprenorphine-Related Complications in Elderly Hospitalised Patients: A Case Series” by Richards et al. 2017 All patients had risk factors such as advanced age, comorbidities, or concurrent use of central nervous system depressants. Management required escalation, with some transferred to high-dependency or intensive care units, and five undergoing attempted naloxone reversal with varying results. The authors emphasize buprenorphine’s potential for respiratory depression in vulnerable populations and recommend cautious use, additional monitoring, and patient education for at-risk elderly patients.

What Are the Effects of Buprenorphine/Naloxone Therapy (BT) on Pregnancy?

The side effects of Buprenorphine/Naloxone (Bup/Nal) therapy on pregnancy are primarily centered around the potential for neonatal withdrawal syndrome, respiratory depression, and low birth weight. Neonates exposed to Bup/Nal experience symptoms such as tremors, irritability, poor feeding, and respiratory distress. The incidence of neonatal withdrawal syndrome is higher in infants born to mothers using opioid medications, with 30-80% of infants showing signs as noted by the American College of Obstetricians and Gynecologists (2017) in “ Opioid Use and Opioid Use Disorder in Pregnancy.” In addition, preterm birth and intrauterine growth restriction (IUGR) have been reported in some cases.

Buprenorphine-naloxone crosses the placenta and is present in the fetal circulation in women taking a daily dose greater than 4 mg/1 mg. Fetal exposure to naloxone is lower than buprenorphine, with naloxone levels being undetectable in 45% of infants. Fetal concentrations of the drug are strongly correlated with maternal levels, as outlined by Wiegand et al. 2016 in their study, “Naloxone and Metabolites Quantification in Cord Blood of Prenatally Exposed Newborns and Correlations with Maternal Concentrations.”

How to Choose the Right Buprenorphine/Naloxone Therapist (BT) Near Me in New Jersey?

To choose the right Buprenorphine/Naloxone therapist in New Jersey, start by verifying the therapist’s credentials, ensuring they are licensed and have experience treating opioid use disorder (OUD) with Buprenorphine/Naloxone Therapy (BT). It’s important to check if they specialize in addiction treatment and have a solid understanding of the physical and psychological aspects of opioid dependence, especially if they hold a DATA 2000 waiver certification, which is required to prescribe Buprenorphine.

Between 2015–2017 and 2017–2019, the annual average prevalence of opioid use disorder among young adults aged 18–25 in New Jersey decreased. In 2017–2019, the prevalence stood at 0.5% (approximately 4,000 individuals), aligning with both the regional average (0.5%) and the national average (1.0%), as reported in SAMHSA’s “Behavioral Health Barometer, New Jersey, Volume 6.”

Consider their treatment approach—whether they use a comprehensive, patient-centered model and provide ongoing support. Reviews from other patients, insurance coverage, and proximity to your location are also key factors to consider. If you’re in New Jersey, Better Life Recovery offers tailored BT for addiction treatment, backed by experienced professionals who understand the complexities of OUD.

How Much Does Buprenorphine/Naloxone Therapy (BT) Cost in New Jersey?

Buprenorphine/Naloxone Therapy costs approximately $100 per week in New Jersey. Prices vary subject to location, provider, and individual treatment needs. Preliminary cost estimates from the U.S. Department of Defense provide a useful basis for comparison when considering treatment in a certified opioid treatment program (OTP). 

For a stable patient, buprenorphine treatment, which includes medication and twice-weekly visits, costs around $115 per week or $5,980 annually. In contrast, naltrexone treatment in an OTP, which encompasses the drug, administration, and related services, totals approximately $1,176.50 per month or $14,112 annually, as provided by the National Institute on Drug Abuse (2018).

What Federal Regulations Govern Buprenorphine/Naloxone Therapy (BT)?

The federal regulations that govern Bup/Nal therapy are the Drug Addiction Treatment Act (DATA) of 2000, the Controlled Substances Act (CSA), the Substance Abuse and Mental Health Services Administration (SAMHSA) certification, the Federal Food, Drug, and Cosmetic Act (FDCA), and the Comprehensive Addiction and Recovery Act (CARA) of 2016, as gleaned from the United States Government Accountability Office (2016) in the “Report to the Majority Leader, U.S.

Senate.” These federal regulations are designed to ensure that Buprenorphine/Naloxone therapy is provided safely and effectively while preventing misuse and ensuring broad access to treatment.

The common federal regulations that govern Buprenorphine/Naloxone therapy (BT) are:

• Drug Addiction Treatment Act (DATA) of 2000: This regulation allows qualified physicians to prescribe buprenorphine and buprenorphine-naloxone for opioid use disorder treatment. It aims to expand access to treatment in office-based settings while ensuring proper training and certification of prescribing providers.
• Controlled Substances Act (CSA): The CSA categorizes substances based on their potential for abuse and medical utility. Buprenorphine is classified as a Schedule III controlled substance, which means it has a recognized medical use but it elicits physical dependence or misuse.
• Substance Abuse and Mental Health Services Administration (SAMHSA) Certification: This regulation mandates that treatment programs and providers administering buprenorphine must be SAMHSA-certified. Certification ensures that the programs adhere to federal guidelines for providing evidence-based addiction treatment.
• Federal Food, Drug, and Cosmetic Act (FDCA): This law governs the approval and regulation of pharmaceutical drugs, including buprenorphine/naloxone combinations, ensuring their safety and effectiveness before being marketed.
• The Comprehensive Addiction and Recovery Act (CARA) of 2016: CARA expanded access to medications like buprenorphine by allowing qualified providers to prescribe it to more patients, thus enhancing treatment accessibility for opioid use disorder.

Should I Choose Buprenorphine/Naloxone Therapy (BT) or Cognitive Behavioral Therapy (CBT) for Addiction Treatment?

You should choose Buprenorphine/Naloxone Therapy (BT) for addiction treatment if you have moderate to severe opioid dependence, need physical withdrawal management, require medical stabilization, or face a high risk of relapse. On the other hand, select Cognitive Behavioral Therapy (CBT) if you have a mild substance use disorder, need behavioral modification, or necessitate trauma processing. For best results, many patients benefit from combining both therapies.

Randomized studies on behavioral interventions in office-based buprenorphine treatment discovered mixed results, with four studies showing no added benefit alongside medical management and four indicating benefits from contingency management. High-quality medical management suffices for some, but a stepped-care approach is recommended for patients struggling early in treatment. With retention rates rarely exceeding 50% at six months, innovative strategies are needed to power retention and bolster outcomes, as mentioned by Carroll K. and Weiss R. 2017 in “The Role of Behavioral Interventions in Buprenorphine Maintenance Treatment: A Review.”

Can Buprenorphine/Naloxone Therapy (BT) Treat Alcohol Addiction?

Yes, buprenorphine/naloxone therapy can treat alcohol addiction based on studies, such as the one conducted by Ciccocioppo et al., circa 2006, but its use in this context is not yet widely established or FDA-approved; low doses of buprenorphine (0.03–0.3 mg/kg) accelerate alcohol consumption, while higher doses (3.0–6.0 mg/kg) reduce it by activating the NOP receptor system.

Blocking this receptor prevents the higher doses from cutting alcohol intake, implying that buprenorphine’s effect on the NOP system aids in treating alcohol addiction, as shown by Ciccocioppo et al. (2006) in “Buprenorphine Reduces Alcohol Drinking Through Activation of the Nociceptin/Orphanin FQ-NOP Receptor System.”No,  buprenorphine/naxolone therapy pointedly targets opioid dependency by combining buprenorphine, a partial opioid agonist, with naloxone, an opioid antagonist, to chip away at withdrawal symptoms and preclude misuse.